---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-165170"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T01:23:11.062088+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement

## Summary
- Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.
- Concurrent $75.0M private placement from investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors.
- Legacy Inmagene holders own ~55% (pre-financing) or ~43.1% (post-financing); Ikena holders own ~45% (pre) or ~35.3% (post); new investors own ~21.6%.
- ImageneBio to advance IMG-007 Phase 2b trial in moderate-to-severe atopic dermatitis; topline readout expected Q4 2026.
- Kristin Yarema, Ph.D. appointed CEO; Ikena implemented a 1-for-12 reverse stock split prior to closing.

## SEC filing metadata
- accession: 0001193125-25-165170
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312525165170/0001193125-25-165170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312525165170/d62567d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-165170
- JSON: https://secwatch.observer/filing/0001193125-25-165170.json
- Plain text: https://secwatch.observer/filing/0001193125-25-165170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.